Alumis Inc. · NASDAQ:ALMS
Alumis — Technical Presentation (September 2024)
14 slides from Alumis's technical presentation, September 2024
Slide 1: Efficacy and Safety of ESK-001, a Highly Selective Oral TYK2 Inhibitor, in Plaque Psoriasis
Efficacy and Safety of ESK-001, a Highly Selective Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Phase 2 results through Week 28 Andrew Blauvelt,1 Steven Kempers,2 Elena Hitraya,3 Michelle Bettinger,3 Roman G. Rubio,3 Nicholas E. Vlahakis,3 Grace Ma,3 and Kim A. Papp4 1 Blauvelt Consu
Slide 2: Conflicts of Interest
Conflicts of Interest Dr. Blauvelt has served as a speaker (received honoraria) for Eli Lilly and Company and UCB, has served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Blu
Slide 3: ESK-001: Selective Oral Allosteric TYK2i Achieves Maximal TYK2 Inhibition for 24 hours
ESK-001: A Selective Oral Allosteric TYK2i Achieves Maximal TYK2 Inhibition for 24 hours at 40 mg BID dosing Inhibition of SIGLEC1, novel TYK2 PD biomarker* ESK-001 Allosteric binding TYK2 Kinase active JH2 domain JH1 domain ESK-001, a highly selective allosteric TYK2 inhibitor 〉High intrinsic TYK2
Slide 4: Potent and Highly Selective Allosteric TYK2 Inhibitor Designed to Achieve Maximal Target Inhibition
ESK-001: Potent and Highly Selective Allosteric TYK2 Inhibitor Designed to Achieve Maximal Target Inhibition Dose-dependent Exposure, Very Low Variability ESK-001 Phase 1 SAD PK Designed to Deliver Potentially Best-in-class Pharmacokinetic Properties 〉 Dose-dependent exposure with very low variabili
Slide 5: STRIDE: Demographics and Baseline Disease Characteristics
ESK-001 STRIDE: Demographics and Baseline Disease Characteristics Well-balanced Across Study Arms Placebo 10 mg QD 20 mg QD 20 mg BID 40 mg QD 40 mg BID Overall (N=38) (N=36) (N=36) (N=40) (N=39) (N=39) (N=228) Age, mean (SD) 49.1 (11.7) 48.8 (12.7) 43.9 (12.0) 47.7 (12.5) 49.5 (10
Slide 6: STRIDE: Primary and Secondary PASI Endpoints Achieved at Week 12
ESK-001 STRIDE: Primary and Secondary PASI Endpoints Achieved at Week 12 with Dose-Dependent Increase in Response Rates PASI 75 PASI 90 PASI 100 Primary Endpoint 100 Proportion of Patients with 90 *** 80 *** *** 70 64.1 Response (%) 60 56.4 56.4 *** *** 50 *** *** 38.5 40 ** 33.3 * 30 * 25.6 25.6 *
Slide 7: RNA-seq Data in Lesional Tissue Confirm Maximal Inhibition
ESK-001 RNA-seq Data in Lesional Tissue Confirm Maximal Inhibition Lesional Skin Levels of Key Cytokines & Disease Related Biomarkers Return to Non-lesional Levels Brkic IFNIFN Brkic signature signature IL17A IL17A IL17F IL17F Key TYK2 Pathway IL22 IL23A IL36A IL22 IL23A IL36A Cytokines DEFB4A DEFB4
Slide 8: STRIDE Safety at Week 16
ESK-001 STRIDE Safety at Week 16 Placebo 10 mg QD 20 mg QD 20 mg BID 40 mg QD 40 mg BID Overall (N=38) (N=36) (N=36) (N=39) (N=39) (N=39) (N=227) Subjects with ≥1 TEAE 15 ( 39.5) 19 ( 52.8) 14 ( 38.9) 18 ( 46.2) 19 ( 48.7) 25 ( 64.1) 110 ( 48.5) Subjects with ≥1 SAE 0 1 (2.8) 0 3 ( 7.7) 1 (2.6) 0 5
Slide 9: 95% of Eligible STRIDE Subjects Continued in OLE Study
ESK-001 95% of Eligible STRIDE Subjects Continued in OLE Study Open Label Extension Trial 228 204 165* ESK-001 40 mg QD (N=82) Randomized Subjects Eligible Phase 2 STRIDE Completing Subjects ESK-001 40 mg BID (N=82) Subjects STRIDE Entering OLE Day 1 Wk Wk Wk Wk Wk Wk Quarterly End of 4 Study / 9 30
Slide 10: OLE Safety Summary at Week 28
ESK-001 OLE Safety Summary at Week 28 ESK-001 40 mg QD ESK-001 40 mg BID Overall (N=82) (N=82) (N=164) Subjects with ≥ 1 TEAE 41 (50.0) 45 (54.9) 86 (52.4) Subjects with ≥ 1 TE SAE 1 (1.2) 3 (3.7) 4 (2.4) Deaths 0 0 0 Subjects with TEAE leading 0 4 (4.9) 4 (2.4) to treatment discontinuation Subjects
Slide 11: STRIDE and OLE Efficacy: PASI Responses with 40mg BID
ESK-001 Stride and OLE Efficacy: Continued Exposure with ESK-001 40mg BID Achieves Significant Increases in PASI Responses OLE Treatment: ESK-001 40 mg BID (mITT Analysis Set) 100 93.0 STRIDE Washout Open Label Extension 89.2 90.3 20 mg BID 40 mg BID 40 mg QD 82.7 80 40 mg BID Placebo 81.7 81.5 71.8
Slide 12: STRIDE and OLE Efficacy: sPGA Responses with 40mg BID
ESK-001 Stride and OLE Efficacy: Continued Exposure with ESK-001 40mg BID Achieves Significant Increases in sPGA Responses OLE Treatment: ESK-001 40 mg BID (mITT Analysis Set) 100 STRIDE Washout Open Label Extension 20 mg BID 40 mg BID 40 mg QD 76.1 80 40 mg BID 72.2 Placebo 68.9 Patient with Respon
Slide 13: 40mg QD Results in Substantially Lower PASI Responses Compared to 40mg BID
ESK-001 Continued Exposure with ESK-001 40mg QD Results in Substantially Lower PASI Responses Compared to 40mg BID OLE Treatment: ESK-001 40 mg QD (mITT Analysis Set) 100 STRIDE Washout Open Label Extension 20 mg BID 40 mg QD 40 mg QD 80 40 mg BID 72.9 Placebo 69.9 62.8 Patient with Response (%) 60
Slide 14: Conclusions
Conclusions STRIDE and OLE studies demonstrate ESK-001 is a clinically effective and generally safe oral therapy for the treatment of patients with moderate-to-severe plaque psoriasis Efficacy Summary 〉Maximal TYK2 inhibition achieved across entire dosing period with highest 40 mg BID dose 〉STRIDE: